Asset profile
Tovinontrine
Small molecule
Evidence outlook · lead readout
NCT06215911 · Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06215911: The study randomized 557 participants to three tovinontrine dose groups or placebo and used quadruple blinding, providing a well-controlled design. However, its primary endpoint was the surrogate biomarker NT-proBNP rather than a clinical or endoscopic outcome, and no primary comparison results are available.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.